Feedback
FOTODITAZIN
Innovation in Medicine
Research
Clinical reserches of the drug "FOTODITAZIN®" were successfully completed at leading medical institutions of Russian Federation including:
  • FSBI "Medical Radiological Research Center" Ministry of Health of Russian Federation;
  • FSBI "The Professor N.N.Petrov Cancer Research Institute" Health Care of Russian Federation;
  • FSI " State Research Laser Center Medecine of Federal Bio-Medical Agency of Ministry of Health and Social Development of the Russian Federation;
  • FSBI "N.N.Blokhin Russian Cancer Research Center" RAMS;
  • FSBI "Research Institute of Influenza" Ministry of Health of Russian Federation;
  • "The Academican N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defence of Russian Federation;
  • FSBI "The Academican S.N. Fyodorov Eye Microsurgery Complex";
  • FSBI "The Professor A.L. Polenov Russian Scienific Research Institute of Neurosurgery;
  • State Institution "Tomsk Cancer Research Institude"
Clinical reserches of the drug "FOTODITAZIN®" were made on more than 1,500 patients, in accordance with Programs and Certificate of analysis of drug "FOTODITAZIN®" approved by Ministry of Health and Social Development of the Russian Federation.
Contacts
Find us in VKontakte Find us in Facebook Find us in Twitter Find us in Instagram Wikipedia Our contacts
Presentation
Tumor fragment surrounded by healthy tissue cells
PHOTODITAZINE injection. Selective accumulation in tumor
Affected tissue irradiation with long-wave red radiation
Reactive oxygen species formation. Induction of necrosis in tumor cells
Selective death of tumor cells surrounded by healthy tissue